A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Latest Information Update: 18 Feb 2025
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SOLACE-kids
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
Most Recent Events
- 23 Oct 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Jul 2024 Planned primary completion date changed from 2 Jan 2025 to 22 Jan 2025.
- 01 May 2024 Planned End Date changed from 12 Jun 2026 to 22 Jan 2025.